Menu

CME Corner

 Advances in Severe Asthma Management

A 2-Part Series

While poor asthma control is frequently attributed to poor adherence to prescribed medications and/or recommended environmental restrictions, 5% to 10% of patients experience poor control because they suffer from an underlying severe asthma pathophysiology characterized by airway inflammation resistant to conventional therapy. Severe asthma is a heterogeneous condition that consists of multiple phenotypes. It is now possible to identify different phenotypes as defined by characteristic clinical symptoms, pathophysiological mechanisms, and biomarkers. These activities will examine the pathophysiology of severe asthma, as well as treatments tailored to various phenotypes.

Target audience:
Allergists, pulmonologists, immunologists, internists, and other clinicians managing severe asthma.

SERIES ACTIVITIES
By selecting the program(s) below, please note you will now be redirected to our partner site.
newsletter Understanding the Immunopathology of Uncontrolled Asthma
Mobile + Online on QuantiaMD
Start
newsletter

The Role of Biologics for Severe Asthma
Mobile + Online on QuantiaMD

Start

 

Faculty
James F. Donohue, MD
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Asthma Clinical Research Center
Baylor College of Medicine
Houston, TX

 

 

 

 

Main Menu
EDITOR'S PICKS